Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 8Other solid neoplasm 2Dermatologic 2Breast 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Unresectable or Metastatic Solid Tumors 1Solid Tumors 1

Interventions

Cisplatin 70Paclitaxel 68pembrolizumab 65Carboplatin 61Irinotecan 59Injections 53Gemcitabine 53Docetaxel 49Fluorouracil 35Cyclophosphamide 35Pemetrexed 34Oxaliplatin 31Capecitabine 30Bevacizumab 29Leucovorin 27atezolizumab 23Nivolumab 23tislelizumab 19Etoposide 18Cetuximab 17durvalumab 16Temozolomide 16Bortezomib 16alvocidib 15Topotecan 15olaparib 14Sorafenib 14Rifampin 14Itraconazole 14Erlotinib Hydrochloride 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × parsaclisib × Other solid neoplasm × Clear all
NCT03589651 2023-02-21

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
83 enrolled
Other solid neoplasm

Unresectable or Metastatic Solid Tumors

NCT02559492 2019-09-25

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Terminated
142 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡